Key result
Interferon-beta treatment in Afro-Caribbean patients with multiple sclerosis reduced the annual relapse rate from 1.29 to 0.83 after 2 years of treatment.
Why the study?
Does interferon-beta reduce relapse rates in Afro-Caribbean patients with multiple sclerosis?
Cohort (n=76)
Does interferon-beta reduce relapse rates in Afro-Caribbean patients with multiple sclerosis?
Interferon-beta treatment reduces annual relapse rates in Afro-Caribbean MS patients but may not be strong enough to fully control the disease in this population with a worse prognosis.
Answers are grounded in this paper and cite their sources.
May support interferon-beta consideration in this population; hypothesis-generating and requires randomized confirmation before practice change.
Background. Multiple sclerosis (MS) patients of African ancestry have a more aggressive disease course than white patients and could be resistant to interferon-beta (INFB). Methods. We studied the impact of INFB in treatment-naive Afro-Caribbean (AC) with clinically definite MS using our European Database for Multiple Sclerosis (EDMUS) (2003-2010). Main outcome measures were annual relapse rate after 2 years of treatment, proportion of exacerbation-free subjects 48 weeks after initiating INFB, and time to first relapse. Results. 76 AC-MS (59F/17M) were identified. Annual relapse rate of 1.29 decreased to 0.83 (-35.6%) after 2 years of treatment. The proportion of relapse-free patients at 48 weeks was 46.2%. Median time to first relapse was 52 weeks. Conclusion. INFB is not strong enough to control AC-MS patients in many cases which is problematic in a population of worse MS prognosis.
No takes yet. Share an insight, caveat, or question.
Jeannin et al. (2011) conducted a cohort in Multiple Sclerosis (n=76). Interferon-beta (INFB) vs. Pre-treatment baseline was evaluated on Annual relapse rate after 2 years of treatment (-35.6%). Interferon-beta treatment in Afro-Caribbean patients with multiple sclerosis reduced the annual relapse rate from 1.29 to 0.83 after 2 years of treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: